Abstract:Short-term trials with the antioxidant thioctic acid (TA) appear to improve neuropathic symptoms in diabetic patients, but the long-term response remains to be established. Therefore, Type 1 and Type 2 diabetic patients with symptomatic polyneuropathy were randomly assigned to three treatment regimens: (1) 2 x 600(mg of TA (TA 1200), (2) 600)mg of TA plus placebo (PLA) (TA 600) or (3) placebo and placebo (PLA). A trometamol salt solution of TA of 1200 or 600 mg or PLA was intravenously administered once daily for five consecutive days before enrolling the patients in the oral treatment phase. The study was prospective, PLA-controlled, randomized, double-blind and conducted for two years. Severity of diabetic neuropathy was assessed by the Neuropathy Disability Score (NDS) and electrophysiological attributes of the sural (sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP)) and the tibial (motor nerve conduction velocity (MNCV), motor nerve distal latency (MNDL)) nerve. Statistical analysis was performed after independent reviewers excluded all patients with highly variable data allowing a final analysis of 65 patients (TA 1200: n = 18, TA 600: n = 27; PLA: n = 20). At baseline no significant differences were noted between the groups regarding the demographic variables and peripheral nerve function parameters for these 65 patients. Statistically significant changes after 24 months between TA and PLA were observed (mean +/- SD) for sural SNCV: +3.8 +/- 4.2 m/s in TA 1200, +3.0+/-3.0m/s in TA 600, -0.1+/-4.8m/s in PLA (p < 0.05 for TA 1200 and TA 600 vs. PLA); sural SNAP: +0.6+/-2.5 microV in TA 1200, +0.3+/-1.4 microV in TA 600, -0.7 +/- 1.5 microV in PLA (p = 0.076 for TA 1200 vs. PLA and p < 0.05 for TA 600 vs. PLA), and in tibial MNCV: +/- 1.2 +/- 3.8 m/s in TA 1200, -0.3 +/- 5.2 m/s in TA 600, 1.5 +/- 2.9 m/s in PLA (p < 0.05 for TA 1200 vs. PLA). No significant differences between the groups after 24 months were noted regarding the tibial MNDL and the NDS. We conclude that in a subgroup of patients after exclusion of patients with excessive test variability throughout the trial, TA appeared to have a beneficial effect on several attributes of nerve conduction.

Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.

Effects Of"lingyi Capsule"on Early Diabetic Peripheral Neuropathy:A Randomized Controlled Multi-center Double-Blind Clinical Trial

Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on symptoms of diabetic peripheral neuropathy

Efficacy of acetyl-levo-carnitine for diabetic peripheral neuropathy in adults: a systematic review and network meta-analysis

Acetyllevocarnitine hydrochloride for the treatment of diabetic peripheral neuropathy: A phase 3, randomized clinical trial in China

Meta-analysis of Methylcobalamin Alone and in Combination with Lipoic Acid in Patients with Diabetic Peripheral Neuropathy

The protective effect of Alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose

A Prospective Study to Evaluate the Efficacy and Safety of Oral Acetyl-L-carnitine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy.

A Systematic Review and Meta-Analysis of Α-Lipoic Acid in the Treatment of Diabetic Peripheral Neuropathy.

Clinical Efficacy and Safety of Epalrestat in Diabetic Neuropathy—a Multicenter Randomized Controlled Clinical Trial

Disease-modifying therapies for diabetic peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials

[Curative effect of alpha-lipoic acid on peripheral neuropathy in type 2 diabetes: a clinical study]

Oral Α-Lipoic Acid Combined with Methylcobalamin in Treatment of Diabetic Peripheral Neuropathy

Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy

Clinical Observation onα-lipoic Acid,PE1,and Mecobalamin for Treatment of Diabetic Peripheral Neuropathy

Clinical Effect of Different Dose of Methyl Cobalamin Combined GM1 in Treatment of Diabetic Peripheral Neuropathy Patients

Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)

Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy

Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy

Comparison of the curative effect of different regimens on diabetic peripheral neuropathy